Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
(Mobilise-D) brings together clinicians, scientists, prominent academic centres, businesses, and the
world’s largest pharmaceutical and medical industries to revolutionise assessment of mobility loss
using digital technology, leading to a game changer for clinical trials and clinical management of
mobility.
Imagine being able to monitor your mobility and health with the help of small sensors worn on your
body, coupled with personalized algorithms – and to do this on a daily basis, without the need to
see your physician or go to a clinic. Impossible?
The overarching objectives of Mobilise-D are threefold:
(1) deliver a valid solution for real-world digital mobility assessment;
(2) validate digital mobility outcomes to predict clinical endpoints in Chronic Obstructive Pulmonary Disease, Parkinson’s Disease, Multiple Sclerosis, Proximal Femoral Fracture Recovery, and Congestive Heart Failure;
(3) obtain key regulatory and health stakeholder approval for digital mobility assessment.
(1) deliver a valid solution for real-world digital mobility assessment;
(2) validate digital mobility outcomes to predict clinical endpoints in Chronic Obstructive Pulmonary Disease, Parkinson’s Disease, Multiple Sclerosis, Proximal Femoral Fracture Recovery, and Congestive Heart Failure;
(3) obtain key regulatory and health stakeholder approval for digital mobility assessment.
 and Prof Lynn Rochester (r).JPG)
.jpg){kind=logo}
.png)
